GH Research (GHRS) Profit After Tax (2020 - 2026)
GH Research (GHRS) posted quarterly Profit After Tax of -$14.1 million for Q4 2025, down 60.61% year-over-year from -$35.9 million in Q4 2024, and down 0.83% quarter-over-quarter from -$14.0 million in Q3 2025.
Analysis
GH Research (GHRS) Profit After Tax (2020 - 2026) Analysis & Trends
GH Research's Profit After Tax history runs 6 years deep, the most recent figure standing at -$14.1 million for Q4 2025.
- In Q4 2025, Profit After Tax fell 60.61% year-over-year to -$14.1 million; the TTM figure through Dec 2025 stood at -$48.3 million (down 23.86% YoY), while the FY2025 annual figure was -$48.3 million, down 23.86% from the prior year.
- Profit After Tax for Q4 2025 stood at -$14.1 million, down from -$14.0 million in the prior quarter.
- The five-year high for Profit After Tax was $334000.0 in Q2 2022, with the low at -$16.6 million in Q4 2022.
- The 5-year median for Profit After Tax is -$8.4 million (2022), against an average of -$7.8 million.
- The sharpest annual moves came in 2021 and 2022: Profit After Tax tumbled 19066.67% in 2021, then jumped 168.72% in 2022.
- GH Research's Profit After Tax stood at -$5.7 million in 2021, then tumbled by 192.57% to -$16.6 million in 2022, then jumped by 32.04% to -$11.3 million in 2023, then advanced by 21.91% to -$8.8 million in 2024, then plunged by 60.61% to -$14.1 million in 2025.
- Business Quant data shows GHRS's Profit After Tax at -$14.1 million in Q4 2025, -$14.0 million in Q3 2025, and -$9.3 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -16.62 Mn |
| 10 | GH Research | 1.71 Bn | 1.35 Bn | - | -17.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.75 Mn |
| Mar 31, 2026 | -18.23 Mn |
| Dec 31, 2025 | -14.35 Mn |
| Sep 30, 2025 | -14.12 Mn |
| Jun 30, 2025 | -8.91 Mn |
| Mar 31, 2025 | -10.22 Mn |
| Dec 31, 2024 | -11.17 Mn |
| Sep 30, 2024 | -9.58 Mn |
| Jun 30, 2024 | -10.93 Mn |
| Mar 31, 2024 | -9.50 Mn |
| Dec 31, 2023 | 58.85 Mn |
| Sep 30, 2023 | -7.86 Mn |
| Jun 30, 2023 | -9.30 Mn |
| Mar 31, 2023 | -8.54 Mn |
| Dec 31, 2022 | -807,000.00 |
| Sep 30, 2022 | -6.91 Mn |
| Jun 30, 2022 | -6.72 Mn |
| Mar 31, 2022 | -8.02 Mn |
| Dec 31, 2021 | 18.84 Mn |
| Sep 30, 2021 | -2.85 Mn |